Panelists discuss how accurate risk stratification using clinical and molecular prognostic tools like DIPSS, MIPSS70, and GIPSS guides personalized treatment decisions in myelofibrosis, ranging from ...

Panelists discuss how clinical trial data from the COMFORT studies supports using Janus kinase (JAK) inhibitors such as ...

Optimal Jakafi dosing in myelofibrosis patients led to improved efficacy and manageable safety, with better spleen response rates and overall survival in the as-expected dosing group. The study ...

Reduction in spleen volume of ≥35% from baseline at week 24 was met in 65.9 and 35.2% of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. HealthDay ...